← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Planet Biotechnology, Inc.
Hayward, CA
$34,308,841
Total funding
36
Grants
Funding over time
peak $3.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,308,841 · 36
By mechanism
R44$18,282,390 · 6
R01$5,835,605 · 2
R43$4,572,147 · 19
R41$3,115,627 · 7
U01$2,315,307 · 1
R34$187,765 · 1
Investigators at Planet Biotechnology, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Botulinum Toxin Plantibodies$1,818,914
R44 · FY2007 · AI
Novel Therapy for Pulmonary Anthrax$1,757,320
R44 · FY2007 · AI
Botulinum Toxin Plantibodies$1,660,566
R44 · FY2006 · AI
Botulinum Toxin Plantibodies$1,614,009
R44 · FY2008 · AI
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against$1,578,528
R01 · FY2011 · AI
An Immunoadhesin Therapy for Inhalational Anthrax$1,345,359
U01 · FY2009 · AI
Final preclinical development of an immunoadhesin therapy for inhalation anthrax$1,230,830
R01 · FY2012 · AI
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against$1,166,055
R01 · FY2012 · AI
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against$1,145,064
R01 · FY2013 · AI
Novel Therapy for Pulmonary Anthrax$1,004,838
R44 · FY2006 · AI
Novel Therapy for Pulmonary Anthrax$1,000,000
R44 · FY2011 · AI
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$1,000,000
R44 · FY2022 · AI
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$1,000,000
R44 · FY2023 · AI
Novel Therapy for Pulmonary Anthrax$1,000,000
R44 · FY2010 · AI
Novel Therapy for Pulmonary Anthrax$995,532
R44 · FY2012 · AI
An Immunoadhesin Therapy for Inhalational Anthrax$969,948
U01 · FY2010 · AI
An immunotherapeutic to prevent gonorrhea$928,633
R44 · FY2021 · AI
Novel Therapy for Pulmonary Anthrax$827,103
R44 · FY2008 · AI
A MERS-CoV Receptor Decoy$801,833
R44 · FY2015 · AI
An immunotherapeutic to prevent gonorrhea$798,475
R44 · FY2020 · AI